Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2011

View Archived Issues

Final data disclosed from phase II NKTR-102 trial in metastatic breast cancer

Spanish university identifies new biomarker of brain abnormalities in schizophrenia

HPI-1-encapsulating polymeric nanoparticle tested in preclinical models of HCC

Pfizer reports pivotal data on tofacitinib in rheumatoid arthritis

New modified ADAM-derived polypeptides disclosed by USC

Researchers optimize Mer inhibitors for treatment of acute lymphoblastic leukemia

Preclinical and phase I data presented on insulin sensitizer LIM-0705

Several trials assess Anacor's boron-based therapies in healthy subjects and psoriasis

Scientists at BMS prepare novel agents for hepatitis C

New bradykinin B1 receptor antagonists synthesized

Researchers at Merck & Co. disclose new AMPK activators

Novel PLK1 inhibitors claimed by Boehringer Ingelheim Pharma

Ironwood Pharmaceuticals patents new GC-C agonists

Transcept Pharmaceuticals plans next resubmission of Intermezzo NDA

BioAlliance reports preliminary phase I data on AMEP biotherapy

Single-dose NeoVisc approved for sale in Europe

Daiichi Sankyo and AstraZeneca launch Nexium capsules in Japan

Mitsubishi Tanabe and Janssen to market Simponi in Japan

Cempra Pharmaceuticals reports data from phase II solithromycin trial

FDA grants new orphan drug status to Revimmune

FDA grants two fast track designations to QLT's oral synthetic retinoid

Soligenix reports on recent data safety monitoring board review of orBec study

Japanese MHLW grants additional approval to CellCept

Thallion reports on phase II SHIGATEC trial

Takeda advances TAK-438 into phase III trials in Japan

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...